Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Doug Leipold"'
Autor:
Ben-Quan Shen, Shab Masih, Brandon Latifi, Isabel Figueroa, Carl Ng, Doug Leipold, Victor Yip, Amrita V. Kamath
Publikováno v:
Drug Metabolism and Disposition. 48:1247-1256
Anti-Ly6E-seco-cyclopropabenzindol-4-one dimer antibody-drug conjugate (ADC) has been reported to form an adduct with α1-microglobulin (A1M) in animal plasma, but with unknown impact on ADC PK and tissue distribution. In this study, we compared the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::945bc3da68bd20d4c91007d4f9bab16e
https://doi.org/10.1124/dmd.120.000145
https://doi.org/10.1124/dmd.120.000145
Autor:
Victor, Yip, Isabel, Figueroa, Brandon, Latifi, Shab, Masih, Carl, Ng, Doug, Leipold, Amrita, Kamath, Ben-Quan, Shen
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 48(12)
Anti-Ly6E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2de2d3505eb45e04d58c7ff7b078641c
https://pubmed.ncbi.nlm.nih.gov/33020064
https://pubmed.ncbi.nlm.nih.gov/33020064
Autor:
Melissa Schutten, Keyang Xu, Bing Zheng, Aimee Fourie-O'Donohue, Hong Wang, Katherine R. Kozak, Steve R. Leong, Amrita V. Kamath, Andrew Polson, Isabel Figueroa, Montserrat Triguero-Carrasco, Doug Leipold
Publikováno v:
mAbs. 10:738-750
For antibody-drug conjugates (ADCs) that carry a cytotoxic drug, doses that can be administered in preclinical studies are typically limited by tolerability, leading to a narrow dose range that can be tested. For molecules with non-linear pharmacokin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20819920a0a5afe80cdde11c5bc6e8a1
https://doi.org/10.1080/19420862.2018.1465160
https://doi.org/10.1080/19420862.2018.1465160
Autor:
Kalli C. Catcott, Susan Clardy, Jack Sadowsky, Rebecca K. Rowntree, Naniye Malli Centibas, Ling Xu, Andy Polson, Kenneth Avocetien, Tyler Carter, Mark Nazzaro, Dokyong \\'DK\\' Kim, Thomas H. Pillow, Neelie Zacharias, Cong Wu, Jeffrey Zurita, Elizabeth Ditty, Stephen Bradley, Alex Uttard, Bingfan Du, William S. Sawyer, Doug Leipold, Gail Lewis Phillips, LiuLiang Qin, Kelly Slocum, Geoffrey Del Rosario, Ginny Li, Shang-Fan Yu, David Lee, Radha Iyengar, Marc Damelin, Dorin Toader, Timothy B. Lowinger
Publikováno v:
Molecular Cancer Therapeutics. 20:P167-P167
Key defining attributes of an antibody-drug conjugate (ADC) include the choice of targeting antibody, linker, and the drug-to-antibody ratio (DAR). The choice of DAR, within the constraints of acceptable physicochemical properties for the given platf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::935b7e76f6213d4a5e30f27ebae7723c
https://doi.org/10.1158/1535-7163.targ-21-p167
https://doi.org/10.1158/1535-7163.targ-21-p167
Autor:
Katherine R. Kozak, Siao Ping Tsai, Doug Leipold, Luke Masterson, Hui Yao, Stefan Steinbacher, Jim Nonomiya, Keyang Xu, Helga Raab, Vishal Verma, Binqing Wei, Jeff Lau, Tao Wang, Janet Gunzner-Toste, Shang-Fan Yu, John A. Flygare, Thomas H. Pillow, Leanna Staben, John S. Wai, Zijin Xu, Brian Safina, Gail Dianne Phillips, Philip Howard, Jing Wang, Dian Su, Josefa Chuh, Jinhua Chen, Guiling Zhao, Guangmin Li, Rachana Ohri, Yichin Liu, Amrita V. Kamath, Charles Eigenbrot
Publikováno v:
Journal of Medicinal Chemistry. 61:989-1000
Antibody-drug conjugates (ADCs) have become an important therapeutic modality for oncology, with three approved by the FDA and over 60 others in clinical trials. Despite the progress, improvements in ADC therapeutic index are desired. Peptide-based A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ec0f3685ed5ba96d277235ba33db5f5
https://doi.org/10.1021/acs.jmedchem.7b01430
https://doi.org/10.1021/acs.jmedchem.7b01430
Autor:
Yulei Wang, Lisa Barroilhet, Anjali Vaze, Dilip Amin, S. Renee Commerford, Kathleen N. Moore, Michael J. Birrer, Doug Leipold, Erika Hamilton, Judy S. Wang, Eric W. Humke, Amit Garg, William M. Flanagan, Manish Patel, Xuyang Lu, H. A. Burris, Joyce F. Liu
Publikováno v:
Cancer Research. 77:CT009-CT009
Background: MUC16 is a transmembrane protein that is overexpressed by ovarian cancer. The role of MUC16 in the pathogenesis of ovarian cancer is unknown; however, MUC16 may facilitate binding of ovarian tumor cells to mesothelial cells lining the per
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::428473b99daeea6623ef35d24580818f
https://doi.org/10.1158/1538-7445.am2017-ct009
https://doi.org/10.1158/1538-7445.am2017-ct009